PASSAGE BIO INC (PASG)

Company Profile

Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 58 full-time employees. The company went IPO on 2020-02-28. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Company Info

PASSAGE BIO INC

One Commerce Square, 2005 Market Street, 39Th Floor

PHILADELPHIA PENNSYLVANIA 19103

P: 12678660312

CEO: Bruce Goldsmith

Employees: 58

Website: https://www.passagebio.com/